These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 22168282)

  • 1. Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.
    Bugelski PJ; Martin PL
    Br J Pharmacol; 2012 Jun; 166(3):823-46. PubMed ID: 22168282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.
    Martin PL; Bugelski PJ
    Br J Pharmacol; 2012 Jun; 166(3):806-22. PubMed ID: 22168335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The successes and limitations of preclinical studies in predicting the pharmacodynamics and safety of cell-surface-targeted biological agents in patients.
    Polson AG; Fuji RN
    Br J Pharmacol; 2012 Jul; 166(5):1600-2. PubMed ID: 22364106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marketed therapeutic antibodies compendium.
    Reichert JM
    MAbs; 2012; 4(3):413-5. PubMed ID: 22531442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab].
    Guhl G; Díaz-Ley B; Fernández-Herrera J
    Actas Dermosifiliogr; 2008; 99(1):5-33. PubMed ID: 18206084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Tutrone WD
    Cutis; 2003 Jan; 71(1):41-5. PubMed ID: 12553629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.
    Kyriakidis I; Tragiannidis A; Zündorf I; Groll AH
    Mycoses; 2017 Aug; 60(8):493-507. PubMed ID: 28444889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment.
    Lansita JA; Mounho-Zamora B
    Curr Pain Headache Rep; 2015; 19(2):2. PubMed ID: 25681157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.
    Ternant D; Paintaud G
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S37-47. PubMed ID: 16187939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys.
    Boado RJ; Hui EK; Lu JZ; Pardridge WM
    Bioconjug Chem; 2013 Jan; 24(1):97-104. PubMed ID: 23249376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti IL-2 receptor antibody--basiliximab].
    Nakagawa Y; Saitou K; Takahashi K
    Nihon Rinsho; 2005 May; 63 Suppl 5():713-7. PubMed ID: 15954434
    [No Abstract]   [Full Text] [Related]  

  • 12. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erbium:YAG fractional laser ablation for the percutaneous delivery of intact functional therapeutic antibodies.
    Yu J; Kalaria DR; Kalia YN
    J Control Release; 2011 Nov; 156(1):53-9. PubMed ID: 21803083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
    Liu L
    J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by a species-invariant time method.
    Oitate M; Nakayama S; Ito T; Kurihara A; Okudaira N; Izumi T
    Drug Metab Pharmacokinet; 2012; 27(3):354-9. PubMed ID: 22146109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody treatments for multiple sclerosis.
    Rose JW; Foley J; Carlson N
    Curr Neurol Neurosci Rep; 2008 Sep; 8(5):419-26. PubMed ID: 18713579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of mAbs in non-human primates during nonclinical safety assessment.
    van Meer PJ; Kooijman M; Brinks V; Gispen-de Wied CC; Silva-Lima B; Moors EH; Schellekens H
    MAbs; 2013; 5(5):810-6. PubMed ID: 23924803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacology and therapeutic applications of monoclonal antibodies.
    Castelli MS; McGonigle P; Hornby PJ
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00535. PubMed ID: 31859459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation.
    Aktas S; Colak T; Baskin E; Sevmis S; Ozdemir H; Moray G; Karakayali H; Haberal M
    Transplant Proc; 2011 Mar; 43(2):453-7. PubMed ID: 21440732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.